6-K ·Filed Oct 22, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Monitor the November 13 Analyst Day for potential updates on the RESOLVE Phase 1b/2 trial of EP-104GI, which could serve as a catalyst if new data or timelines are shared.
Latest settled — T+1d
EPRX ▼ -9.49% at T+1d
NEUTRAL call -9.49% · α vs SPY -8.96% · entry $7.59 → $6.87
T+1d
-9.49%
call -9.49% · α -8.96%
$6.87
settled 4d ago
T+5d
Pending
in 2d
T+20d
Pending
in 23d
T+60d
Pending
in 3mo
Price Chart
Loading chart...
Executive Summary
Eupraxia announced management participation in several upcoming investor conferences and a virtual Analyst Day focused on EP-104GI for eosinophilic esophagitis. No financial data, clinical results, or material business developments were disclosed.
Key Facts
- Management will present at Craig Hallum Biotech Catalyst Virtual Conference (Oct 22), BIO-Europe (Nov 9-11), Stifel 2026 Healthcare Conference (Nov 10-12), and Jefferies Global Healthcare Conference (Nov 16-19).
- Virtual Analyst Day scheduled for November 13, 2026, to discuss EP-104GI for Eosinophilic Esophagitis.
- No clinical data, financial results, or material corporate developments were announced.
Financial Impact
No financial impact disclosed.
Risk Factors
- No new clinical or financial data provided; stock may trade on conference sentiment rather than fundamentals.
- Early-stage biotech with no approved products; pipeline risk remains high.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006756 |
| Exhibit: exh_991.htm | 0001171843-26-006756 |
| Document: 0001171843-26-006756-index-headers.html | 0001171843-26-006756 |
| Document: 0001171843-26-006756-index.html | 0001171843-26-006756 |
| Document: 0001171843-26-006756.txt | 0001171843-26-006756 |
18 reports for EPRX
71% Hit rate @ T+5 Went positive at some point 5 of 7 best @ T+20▲ +26.24%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $7.59 | awaiting T+5 | — | $6.85 (−9.75%) |
Oct 15, 2026 11d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $6.85 (+1.18%) |
Oct 9, 2026 17d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $6.85 (−8.18%) |
Sep 30, 2026 26d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Sep 30, 2026 26d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Aug 25, 2026 8w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $6.85 (+7.68%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $6.85 (+2.70%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $6.85 (+5.71%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $6.85 (+5.06%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $6.85 (+3.16%) |
Showing 10 of 18
US Market Status
Market Closed — Opens Wed (10h 10m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers